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Summary 
The association of specific HLA-DQ alleles with autoimmunity is correlated with discrete poly- 
morphisms in the HLA-DQ sequence that are localized within sites suitable for peptide recog- 
nition. The polymorphism at residue 57 of the DQB1 polypeptide is of particular interest since 
it may play a major structural role in the formation of a salt bridge structure at one end of the 
peptide-binding cleft of the DQ molecules. This polymorphism at residue 57 is a recurrent fea- 
ture of HLA-DQ evolution, occurring in multiple distinct allelic families, which implies a func- 
tional selection for maintaining variation at this position in the class II molecule. We directly 
tested the amino acid polymorphism at this site as a determinant for peptide binding and for an- 
tigen-specific T  cell stimulation. We found that a single Ala-oAsp amino acid 57 substitution 
in an HLA-DQ3.2 molecule regulated binding of an HSV-2 VP-16-derived peptide. A com- 
plementary single-residue substitution in the peptide abohshed its binding to DQ3.2 and con- 
verted it to a peptide that can bind to DQ3.1 and DQ3.3 Asp-57-positive MHC molecules. These 
binding studies were paralleled by specific T cell recognition of the class II-peptide complex, in 
which the substituted peptide abohshed T  cell reactivity, which was directed to the DQ3.2- 
peptide complex, whereas the same T  cell clone recognized the substituted peptide presented 
by DQ3.3, a class II restriction element differing from DQ3.2 only at residue 57. This struc- 
tural and functional complementarity for residue 57 and a specific peptide residue identifies this 
interaction as a key controlling determinant of restricted recognition in HLA-DQ-specific im- 
mune responses. 
M 
HC class II proteins act as peptide-binding molecules 
for presenting antigenic peptides to T cells. Both pep- 
tide  sequence-specific  and  peptide  sequence-nonspecific 
interactions with the  MHC  molecules  contribute  to  the 
stabilization of the MHC-peptide complex (1-3).  Interac- 
tions ofpeptide main-chain carbonyl and amide groups with 
MHC residues by hydrogen bond and Van der Waals force 
provide the free energy for sequence-nonspecific binding. In- 
teractions ofpeptide side chains with polymorphic residues 
within the binding pockets of the MHC impose peptide- 
binding specificity, which varies for different MHC mole- 
cules. X-ray crystallography of one of these MHC molecules, 
HLA-DR1, indicated there are four major binding pockets 
in the DR1 molecules, termed pockets 1, 4, 6, and 9 (3, 4), 
which accommodate specific anchor residues from the pep- 
fide. Much of the sequence polymorphism among HLA-DR 
alleles clusters in these pockets, providing the structural ba- 
sis by which different molecules bind and present different 
antigens.  Preferential  interactions  between  polymorphic 
pockets and specific  anchor residues create peptide  "mo- 
tifs" in which the pattern of residues within a peptide se- 
quence dictates its preferential MHC binding partner (5-7). 
In  contrast  to  HLA-DR,  binding  moti~  for  HLA-DQ 
molecules remain largely unknown (8-10), although poly- 
morphisms in binding pockets that distinguish among DQ 
molecules are associated with several autoimmune diseases, in- 
chiding type 1 diabetes mellitus (11,  12). In particular, the 
HLA-DQ3.2  molecule, highly associated  with  disease,  is 
highly homologous to two naturally occurring alleles, HLA- 
DQ3.1  and HLA-DQ3.3. These three DQ molecules have 
identical DQcx chains (DQAI*0301) and DQ[3 chains with 
extremely high amino acid sequence similarity; the DQ3.2 
and DQ3.3  [3  alleles  (DQBI*0302  and DQBI*0303,  re- 
spectively)  differ only in  an  Ala---)Asp polymorphism at 
codon 57,  whereas the DQ3.1[3  allele  (DQBI*0301)  en- 
codes Asp 57 and three additional polymorphisms at positions 
13, 26, and 45. The aspartic residue in DQ3.1  and DQ3.3 
hkely interacts with an arginine at residue 79 of the DQA1 
chain to form a salt bridge by analogy with a similar struc- 
ture in HLA-DR1  (3), whereas DQ3.2 lacks this interac- 
tion. An influence of this potential salt bridge in DQ  on 
peptide binding has been suggested (13) but not yet directly 
tested. We have analyzed these three different DQ alleles to 
examine peptide-binding specificity to DQ  molecules in- 
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cific, DQ3.2-restricted  T  cell clone was also used to assess 
the functional consequences of modulating peptide binding 
on TCR interaction with the DQ-peptide complex. 
Materials and Methods 
Cell Lines.  EBV-transformed B cell lines were obtained from 
the  X  International  Histocompatibility  Workshop.  The  VP16- 
restricted T cell clone 2A.334 was derived from the HSV-2 lesion 
of  a  patient  (HLA  DQAI*0301/DQBI*0302,  DQAI*0103/ 
DQBI*0603) with herpetic vesicles. Briefly, cells from herpetic ves- 
icles were centrifuged through Ficoll-Hypaque density gradient; 
10  s cells were stimulated  in bulk with 1.5 ￿  10  s allogeneic  irradi- 
ated PBMC in R.PMI 1640 supplemented with 10% heat-inacti- 
vated pooled human serum,  1% penicillin-streptomycin,  2  mM 
r-glutamine, PHA (0.4 ~g/ml), and human IL-2 (50 U/ml; Schi- 
aperelli Biosystems, Fairfield, NJ) (14). After 16 d of growth, 5 ￿ 
10  s cells were restimulated  with HSV-2 antigen and 5 ￿  10  s au- 
tologous irradiated  PBMC in  1-ml cultures,  and  10-12 d  later 
they were cloned at 1 cell/well using PHA, IL-2, and allogeneic 
feeder cells (15). Clones judged to have HSV-2 type-specific re- 
sponses (stimulation  index with HSV-2 antigen >4.0 and no spe- 
cific stimulation with HSV-1 antigen)  were screened for reactiv- 
ity with  HSV-1  ￿  HSV-2 intertypic recombinant virus  RP-2. 
HSV-2 type-specific  T cell clones reactive with RP-2 are specific 
for VP16 (16). 
Peptide-binding Assays.  106  EBV-transformed human  B  cells 
(PR.IESS, DQ3.2; PF, DQ3.1; HID, DQ3.3) were incubated with 
0.5% paraformaldehyde for 10 rain and washed three times in HBSS. 
Cells were then resuspended with 10 p~M biotinylated peptide in 
150 mM citrate-phosphate buffer, pH 4.4,  1 mM PMSF, in a 100 
p~l reaction volume for 24 h at 37~  Cells were washed twice in 
HBSS before lysis in 100 ~,1 buffer containing 0.5% NP-40, 0.15 M 
NaC1, 50 mM Tris,  pH 8.0,  and protease  inhibitors.  The lysates 
were  cleared  by centrifugation,  and  then  transferred  to  96-well 
plates precoated with 10 Izg/ml mAb SPVL3  (specific for HLA- 
DO.) and blocked with 5% FCS in PBS. The lysate was neutralized 
with 100 t~l of 50 mM Tris, pH 8.0, containing 0.02% n-dodecyl 
[3-D-maltoside  and incubated overnight at 4~  The wells were 
then washed with PBS containing 0.02% Tween 20. Europium- 
labeled streptavidin  (Wallac, Gaithersburg,  MD) was added in the 
presence of 200 p~l DELFIA assay buffer (Wallac) and incubated 
at  4~  for 4  h.  After washing,  200  t~l  of enhancement  buffer 
(Wallac) was added, and the resultant fluorescence was measured us- 
ing a DELFIA 1232 fluorometer. Peptides  were provided by Drs. 
R. Burke and M. Tigges (Chiron Corp., Emeryville,  CA) or syn- 
thesized as previously described (17). 
Cytotoxic T Cell Assays.  106 target cells were incubated with 
125 p,  Ci 51Cr and 0.005-5 ~g/ml ofpeptide for 90 min at 37~ 
Cells were washed and plated at 3 ￿  103 cells/wells  into 96-well 
U-bottom plates.  Cloned T  cells were added at an E/T ratio of 
20:1, with a final volume of 200 ~l/well with or without 10 ~g/ 
ml mAb SPV L3 or L243  (specific for HLA-DR). After 4 h  at 
37~  30 p~l ofsupematant was counted using a scintillation counter 
(Lumaplates and Topcount; Packard,  Meriden,  CT). l~esults are 
reported  as percentage  of specific lysis, defined  as  [mean experi- 
mental cpm -  mean spontaneous cpm)/(mean maximum cpm - 
mean spontaneous cpm)]  ￿  100. Assays were performed in tripli- 
cate, and spontaneous release was usually <30% of total release. 
Proliferation Assays.  T  cells (10a/well)  and  autologous  irra- 
diated PBMC (10S/well) as APC were added to a final volume of 
200 ILl ofT cell medium in 96-well U-bottom plates. Peptide was 
used  at a final concentration of 5 Ixg/ml. After 3 d,  [3H]thymi- 
dine (1 p,  Ci/well) was added for 18 h; cells were harvested  with a 
semiautomatic  harvester and counted by liquid scintillation.  Stim- 
ulation index is defined as mean cpm of [3H]thymidine incorpo- 
ration for antigen/mean cpm of [3H]thymidine incorporation for 
control antigen. 
Results and Discussion 
The T  cell clone 2A.334, reactive with VP16, was identi- 
fied by screening HSV-2 type-specific clones with a panel 
of HSV-1  and HSV-2 intertypic recombinant viruses  (16). 
The  specificity of CD4 +  T  cell clone 2A.334 was defined 
using a  set of overlapping peptides  corresponding to amino 
acids 410-469 of VP16 of HSV-2, the region of maximum 
sequence  divergence  between  HSV-2  and  HSV-1.  Initial 
screening  by proliferation assay using overlapping 15-mer 
peptides identified reactivity to VP16  430-444  (Fig.  1 A). 
Subsequent  analysis  of cytolytic activity using  13-mers  de- 
rived from this sequence demonstrated reactivity with 433- 
445, but not 429-441, defining an epitope included within 
the  sequence  DMTPADALDDFDL  (Fig.  1  B).  Fig.  1  C 
summarizes the restriction pattern of this clone, which rec- 
ognized the VP16 433-445 peptide of HSV-2 presented by 
DQAI*0301/DQBI*0302; the cytolytic activity of the clone 
was inhibited by the anti-DQ mAb SPVL3 but not by the 
anti-DR mAb L243. Since neither DQBI*0301 nor DQBI* 
0303  presented  the  HSV-2  peptide  to  clone  2A.334,  we 
tested  these  alleles  in  peptide-binding  assays  with  peptide 
433-445.  Fig.  2  A  shows that the peptide  bound DQBI* 
0302,  but  not DQBI*0301  nor *0303.  Since  the  DQ3.3 
molecule differs  from DQ3.2 only in an Ala-->Asp 57 poly- 
morphism,  this  directly  correlates  variation  at  this  residue 
with altered peptide binding.  To determine which residues 
on the' HSV-2  peptide  likely  interact  with  the  codon  57 
residue,  we  synthesized modified HSV-2 peptides  that re- 
constituted binding to the DQ3.1 and DQ3.3 alleles.  These 
peptide analogues were based on two assumptions:  (a) that 
peptide-binding pockets in DQ and DR molecules should 
be  fairly homologous,  and  (b)  that  the  HSV-2  peptide  is 
held in an extended conformation, similar to the extended 
conformation of the  HA307-319  peptide  in  DR1  (3).  In 
this scenario, an anchor residue in position n of the peptide 
should fit into pocket one, and residues n  +  3, n  +  5, and 
n  +  8 should interact with pockets 4, 6, and 9  of the DQ 
molecule, respectively.  In this model, Asp57  residues  may 
influence  pocket  9  of the  DQ3.1  and  DQ3.3  alleles  by 
forming a  salt  bridge with Arg79 of the  DQot chain.  The 
DQ3.2  molecule,  however,  has  an  alanine  at  codon  57; 
there  are both  steric  and  charge implications  of this poly- 
morphism,  including  the  likelihood  that  the  positively 
charged Arg79 may interact  with  negatively charged resi- 
dues from bound peptide  in the absence of the Asp57 salt 
bridge. 
The sequence of the HSV-2 433--445 peptide  is consis- 
tent with this model: methionine at position 434 may act as 
an anchor residue for pocket 1, and aspartic acid at position 
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Figure  2.  Modulation  of HLA-DQ  binding  by  HSV-2  433-445 
10D--)10A substitution. Binding of 433-445 (A) and 433-445 10A (B) to 
B-LCL that expressed various DQw3 alleles. 
Figure  1.  Peptide  specificity and  restricted  recognition  of  clone 
2A.334. Proliferative response of clone 2A.334 with autologous PBMC as 
APC (A) and cytotoxic activity of clone 2A.334 at an E/T ratio of 20:1 
with EBV-transformed autologous B-LCL as target cells (B) or homozy- 
gous EBV-transformed B-LCL with different DQ alleles as target cells 
(C). Peptides were used at 5 p.g/ml for both proliferative (A) and SlCr re- 
lease assays  (B and C). 
442, corresponding to the n  +  8 residue, may interact with 
pocket 9.  To test this hypothesis, the HSV-2  10A peptide 
was synthesized with D-->A substitution at position 442  (n + 
8) and tested for the ability to bind to the DQ3.1,  DQ3.2 
and DQ3.3  molecules. As shown  in Fig. 2  B,  the HSV-2 
10A peptide bound to both DQ3.1  and DQ3.3 but did not 
bind to DQ3.2, giving a pattern reciprocal to the wild-type 
HSV-2  433--445  peptide (Fig. 2  A). This identifies residue 
442  as  a  key anchor  for binding to  the  three  DQ  alleles, 
complementary to the effect of the polymorphism at codon 
57. To further validate the role of M  at position 434 and D 
at position 442 as anchoring residues for pocket 1 and pocket 
9, respectively, additional HSV peptide analogues were syn- 
thesized. HSV-2 2L and HSV-2 2R contain an L and an R 
substitution  at position 434,  respectively, whereas  HSV-2 
10E and HSV-2 10L have an E  and an L substitution at po- 
sition 442, respectively. These HSV-2 peptide analogues were 
tested for binding to DQ3.2,  DQ3.3,  and DQ3.1  B-LCLs, 
as shown in Fig. 3. The conservative M---)L substitution at 
position 434  (HSV-2 2L) had little influence on binding to 
DQ3.2 compared with the native HSV-2 433-445 peptide, 
whereas there was a substantial decrease in binding with the 
more drastic M-->R substitution in the HSV-2 2R peptide 
(Fig. 3 A). Similarly, a conservative E  substitution at posi- 
tion 442  (HSV-2  10E) bound to DQ3.2  much better than 
HSV-2  10L. As with the HSV-2  10A peptide, which failed 
to bind to DQ3.2 but was capable of binding to DQ3.1  and 
DQ3.3  (Fig. 2  B),  the HSV-2  10L peptide also bound to 
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DQ3.3  and DQ3.1  (Fig.  3,  B and  C).  These results  sub- 
stantiate the assumption that in this peptide, residue 434 is 
the pocket 1 anchor and that a negatively charged residue 
at the n  +  8 position is critical for allele-specific binding to 
DQ3.2. Presumably, in the absence of the Asp57 salt bridge, 
the negatively charged residue at position n  +  8 of  the pep- 
tide can interact with the accessible Arg79 of  the DQcx chain, 
and, conversely, in the presence of the salt bridge, a nega- 
tively charged residue at the n  +  8 position appears to be 
unfavorable for peptide binding. 
These HSV-2 peptide analogues were then tested for rec- 
ognition by T  cell clone 2A.334.  As anticipated from the 
binding  studies,  HSV-2  2L  and  native  433-445  peptide 
stimulated clone 2A.334 with DQ3.2 B-LCL as APC (Fig. 
4, A  and B). The HSV-2 2R peptide, however, was pre- 
sented only at much higher peptide concentration (Fig. 4 C), 
in agreement with the observation that this peptide bound 
less efficiently to DQ3.2.  Peptide analogues with substitu- 
tions at position 442 were also analyzed.  Peptide HSV-2 10E 
(Fig. 4 D) was presented by DQ3.2, like the native HSV-2 
433-445  peptide. The HSV-2  10A and HSV-2  10L ana- 
logues, however, showed no cytolytic recognition by clone 
2A.334 on DQ3.2 target cells (Fig. 4, E and F). These re- 
sults correlated with the lack of  binding of these peptides to 
DQ3.2 B-LCL. However, clone 2A.334 was able to recog- 
nize the HSV-2  10A and HSV-2  10L peptides when they 
were presented by DQ3.3  (Fig.  4,  E  and  F).  Thus, both 
HSV-2 peptides with a negatively charged residue at posi- 
tion 442 complexed with DQ3.2 and also HSV-2 peptides 
with an atiphatic side chain residue at position 442  com- 
plexed with DQ3.3 were recognized by the clone 2A.334, 
indicating  the  generation  of similar  MHC-peptide  com- 
plexes by the structural complementation of  residue 442 and 
codon 57.  Interestingly, though the HSV-2  10A and  10L 
peptides  bound  to  DQ3.1,  these  DQ-HSV-2  complexes 
were not recognized by the 2A.334  clone.  This indicates 
modulation  of T  cell recognition by the additional poly- 
morphic sites, which are unique to DQ3.1, and two alter- 
native  explanations  are  feasible.  Polymorphic residues  13 
and 26 of the DQ3.1  molecule are likely to lie in the floor 
of the peptide-binding groove, such that the HSV-2 pep- 
tides could be presented by the DQ3.1 molecule in a different 
conformation because of these changes. Similar observations 
have  been  reported by  others  for DR.4-restricted  clones 
(18).  Alternatively, the DQ3.1  molecule has  a bulky resi- 
due at position 45,  that,  though located outisde the pep- 
tide-binding groove and the cx helix, may interfere direcdy 
with interaction with the TCR. This alternative is consis- 
tent with previous observations that residue 45 is an immu- 
nodominanat mAb-binding epitope on the  DQ3.1  mole- 
cule (19, 20). 
In sum, we have demonstrated a critical role for the DQI3 
polymorphism at  codon 57  as  a structural and functional 
Figure 3.  Binding  of HSV 433-445 position 2 and 10 analogues to (A) 
DQ3.2, (/3) DQ3.3, and (C) DQ3.1. 
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Figure  4.  Modulation of T cell recognition by HSV 433-445 analogues. SlCr release assays with clone 2A.334 on B-LCL that expressed different 
DQw3 alleles and loaded with (A) HSV-2 433-445, (B) HSV-2 2L, (C) HSV-2 2R, (D) HSV-2 2E, (E) HSV-2 10A, or (F) HSV-2 10L were used as 
targets. 
determinant ofpeptide-specific recognition. This polymor- 
phism is likely to be a major contributor to allelic specific- 
ity,  with  preferential  binding  of Asp-negative  alleles  to 
peptides with negatively charged anchor residues interact- 
ing with the class II pocket. 
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